Clinical Trial Update: Rifaximin in Patients With Monoclonal Gammopathy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating rifaximin in patients with monoclonal gammopathy; status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Deposition Disease
• Monoclonal Gammopathy
• Smoldering Waldenström Macroglobulinemia
• Waldenström Macroglobulinemia

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Emory University | Conditions: IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy | Phase 1 | Status: ACTIVE_NOT_RECRUITING